AEON Biopharma Valuation Multiples
Discover AEON Biopharma's revenue and EBITDA valuation multiples and M&A history.
AEON Biopharma Overview
About AEON Biopharma
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.
Founded
2012
HQ
Employees
5
Website
Financials (LTM)
EV
$10M
Valuation Multiples
Start free trial
AEON Biopharma Financials
AEON Biopharma reported last 12-month revenue of -.
In the same LTM period, AEON Biopharma generated had net loss of ($39M).
AEON Biopharma P&L
In the most recent fiscal year, AEON Biopharma reported revenue of - and EBITDA of ($16M).
AEON Biopharma is unprofitable as of last fiscal year, with EBITDA margin of - and net margin of -.
Financial data powered by Morningstar, Inc.
AEON Biopharma Stock Performance
AEON Biopharma has current market cap of $13M, and enterprise value of $10M.
AEON Biopharma's stock price is $0.27.
AEON Biopharma has an EPS (earnings per share) of $-0.80.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10M | $13M | -1.6% | - | - | - | $-0.80 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAEON Biopharma Valuation Multiples
AEON Biopharma trades at (0.6x) EV/EBITDA.
AEON Biopharma Financial Valuation Multiples
As of August 14, 2026, AEON Biopharma has market cap of $13M and EV of $10M.
AEON Biopharma has a P/E ratio of (0.3x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified AEON Biopharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
AEON Biopharma Margins & Growth Rates
AEON Biopharma decreased net profit by 1% in the last fiscal year.
AEON Biopharma Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
AEON Biopharma Operational KPIs
AEON Biopharma's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $3.3M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
AEON Biopharma Competitors
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
This data is available for Pro users. Sign up to see all AEON Biopharma competitors and their valuation data. Start Free Trial | ||||||
AEON Biopharma VC Funding History
Before going public, AEON Biopharma raised $30M in total equity funding, across 1 round.
AEON Biopharma Funding Rounds
Acquisitions by AEON Biopharma
AEON Biopharma has acquired 1 company to date.
Last acquisition by AEON Biopharma was on December 12th 2022. AEON Biopharma acquired Priveterra for $165M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by AEON Biopharma
| Description | Priveterra is a Cayman Islands-incorporated special purpose acquisition company targeting mergers or acquisitions in the life sciences sector. Sponsored by industry veterans, it raised $230 million in its 2021 IPO on the Nasdaq under ticker PMGM. Focused on biotechnology, diagnostics, and medical devices, Priveterra completed its business combination with Shattuck Labs in 2022, forming a clinical-stage biopharmaceutical company developing bifunctional fusion proteins for immuno-oncology. |
| HQ Country |  |
| HQ City | Fort Lauderdale, FL |
| Deal Date | 12 Dec 2022 |
| Valuation | $165M |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all AEON Biopharma acquisitions and their M&A valuation multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout AEON Biopharma
| When was AEON Biopharma founded? | AEON Biopharma was founded in 2012. |
| Where is AEON Biopharma headquartered? | AEON Biopharma is headquartered in United States. |
| How many employees does AEON Biopharma have? | As of today, AEON Biopharma has over 5 employees. |
| Is AEON Biopharma publicly listed? | Yes, AEON Biopharma is a public company listed on NYSE American. |
| What is the stock symbol of AEON Biopharma? | AEON Biopharma trades under AEON ticker. |
| When did AEON Biopharma go public? | AEON Biopharma went public in 2023. |
| Who are competitors of AEON Biopharma? | AEON Biopharma main competitors include |
| What is the current market cap of AEON Biopharma? | AEON Biopharma's current market cap is $13M. |
| Is AEON Biopharma profitable? | No, AEON Biopharma is not profitable. |
| What is the current net income of AEON Biopharma? | AEON Biopharma's last 12 months net income is ($39M). |
| How many companies AEON Biopharma has acquired to date? | As of August 2026, AEON Biopharma has acquired 1 company. |
| What was the largest acquisition by AEON Biopharma? | $165M acquisition of Priveterra on 12th December 2022 was the largest M&A AEON Biopharma has done to date. |
| What companies AEON Biopharma acquired? | AEON Biopharma acquired Priveterra. |
| In how many companies AEON Biopharma has invested to date? | AEON Biopharma hasn't invested in any companies yet (or none have been disclosed publicly). |
Lists including AEON Biopharma
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.